enGene Holdings: Key Catalysts Incoming For 2026

Impact · against what's priced in

enGene Holdings is positioned for a positive re-rating based on strong clinical efficacy (63% complete response rate) and a concrete regulatory roadmap. The upcoming LEGEND cohort update and H2 2026 BLA submission target provide specific, material catalysts for the stock.

ENGN+0.70

No priced-in read yet

In context

The 63% complete response rate for detalimogene voraplasmid and the target BLA submission in H2 2026 establish a high-conviction path toward commercialization.

Read from the article alone

• biotech
• ENGN
• bla submission
• clinical trials
• fda approval
• nmibc
• oncology

Search tags